ArticleOncotarget2018
Clinical impact of serum soluble SLAMF7 in multiple myeloma.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Pooled it
- Novel DNA methylation signatures of tobacco smoking with trans-ethnic effects.Clinical epigenetics · 2021Pooled it
- Review
- The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance.Molecular diagnosis & therapy · 2026Review
- The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity.Cell communication and signaling : CCS · 2026Article
- Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes.Nature communications · 2025Article
- How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?Immunotherapy · 2025Review
- c-FOS Confers Stem Cell-like Features to Multiple Myeloma Cells in a Bone Marrow Microenvironment.Cells · 2025Article
- Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells.Haematologica · 2024Article
- A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers.International journal of molecular sciences · 2024Review
- SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.Current oncology (Toronto, Ont.) · 2023Review
- Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.Scientific reports · 2023Article
- SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy.Frontiers in immunology · 2023Review
- Effect of repeated bolus and continuous glucose infusion on a panel of circulating biomarkers in healthy volunteers.PloS one · 2022Article
- Chimeric antigen receptor T-cell therapy for multiple myeloma.Frontiers in immunology · 2022Review
- Deglycosylation of SLAMF7 in breast cancers enhances phagocytosis.American journal of cancer research · 2022Article
- Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.Cancers · 2021Review
- Prognostic and predictive biomarker developments in multiple myeloma.Journal of hematology & oncology · 2021Review
- Targeted Therapies for Multiple Myeloma.Journal of personalized medicine · 2021Review
- A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients.International journal of hematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical significance of serum soluble SLAMF7 (sSLAMF7) levels in patients with MM (n=103) and furthermore the impact of sSLMF7 on the antitumor activity of anti-SLAMF7 antibody. Thirty-one percent of MM patients, but not patients with monoclonal gammopathy of undetermined significance and healthy controls, had detectable levels of serum sSLAMF7, which were significantly increased in advanced MM patients. Further, MM in sSLAMF7-postive patients exhibited aggressive clinical characteristics with shorter progression-free survival times in comparison with sSLAMF7-negative patients. In responders to MM therapy, the levels of sSLAMF7 were undetectable or decreased compared with those before treatment. In addition, the anti-SLAMF7 antibody-mediated antibody-dependent cellular cytotoxicity of NK cells against MM cell lines was inhibited by recombinant SLAMF7 protein. Thus, our findings suggest that high concentrations of sSLAMF7, which could transiently suppress the therapeutic effects of elotuzumab, may be a useful indicator of disease progression in MM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.